Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Breast Neoplasms × Estramustine × Clear all

Phase

Status

Withdrawn 1 Unknown 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 28 Neoplasm Metastasis 2 Thromboembolism 1 Sarcoma 1 Prostate Adenocarcinoma 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large-Cell, Immunoblastic 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma 1 Leukemia, Myeloid, Acute 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia 1 Kidney Neoplasms 1 Hodgkin Disease 1 Fibrosarcoma 1 Carcinoma, Renal Cell 1 Burkitt Lymphoma 1 Breast Neoplasms 1

Interventions

Trastuzumab 296 Paclitaxel 277 Cyclophosphamide 266 Docetaxel 242 Capecitabine 158 Doxorubicin 151 Letrozole 137 Tamoxifen 126 Bevacizumab 100 Lapatinib 98 Fulvestrant 97 exemestane 94 Anastrozole 94 Carboplatin 93 Radiotherapy 92 Gemcitabine 82 Epirubicin 82 Vinorelbine 64 Surveys and Questionnaires 62 Fluorouracil 62 palbociclib 59 Exercise 59 Filgrastim 54 pertuzumab 53 Albumin-Bound Paclitaxel 53 Magnetic Resonance Spectroscopy 51 eribulin 50 Everolimus 45 Cisplatin 44 Blood Specimen Collection 43

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02866955 2020-03-09

EFESE

Institut de Cancérologie de Lorraine

Phase 2 Completed

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡